Search

Displaying results 4291 - 4300 of 8517 in total
  1. Drug

    ACT-451840

    go.drugbank.com/drugs/DB13054
    Investigational

    ACT-451840 has been used in trials studying Malaria.

  2. Drug

    Lupeol

    go.drugbank.com/drugs/DB12622
    Investigational

    Lupeol has been investigated for the treatment of Acne.

  3. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  4. Drug

    Vevorisertib

    go.drugbank.com/drugs/DB21481
    Investigational

    Vevorisertib has a monoisotopic molecular weight of 586.32 Da. … Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

  5. Drug

    Piribedil

    go.drugbank.com/drugs/DB12478
    Investigational

    Piribedil has been investigated in Parkinson's Disease.

  6. Drug

    Aleplasinin

    go.drugbank.com/drugs/DB12635
    Investigational

    Aleplasinin has been investigated in Alzheimer Disease.

  7. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  8. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  9. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based

  10. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.